 Connection
Paul Bunn to Deoxycytidine
This is a "connection" page, showing publications Paul Bunn has written about Deoxycytidine.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.541 |
|
|
|
-
Bunn P. New investigative regimens and cytotoxic agents in thoracic cancers: gemcitabine and pemetrexed. Oncology (Williston Park). 2004 Jul; 18(8 Suppl 5):5-11.
Score: 0.218
-
Bunn PA, Lilenbaum R. Chemotherapy for elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2003 Mar 05; 95(5):341-3.
Score: 0.199
-
Simon GR, Bunn PA. Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments. Cancer Invest. 2003; 21(1):87-104.
Score: 0.196
-
Bunn PA. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J Clin Oncol. 2002 Sep 15; 20(18 Suppl):23S-33S.
Score: 0.192
-
Bunn PA. Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors). Semin Oncol. 2002 Jun; 29(3 Suppl 9):17-22.
Score: 0.189
-
Bunn PA. Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer. Semin Oncol. 1999 Feb; 26(1 Suppl 4):25-30.
Score: 0.150
-
Bunn PA. The emerging role of gemcitabine in lung cancer. Semin Oncol. 1997 Jun; 24(3 Suppl 8):S8-1.
Score: 0.133
-
Bunn PA. The emerging role of gemcitabine in lung cancer: part I. Semin Oncol. 1997 Apr; 24(2 Suppl 7):S7-1.
Score: 0.132
-
Monnerat C, Le Chevalier T, Kelly K, Obasaju CK, Brahmer J, Novello S, Nakamura T, Liepa AM, Bozec L, Bunn PA, Ettinger DS. Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Clin Cancer Res. 2004 Aug 15; 10(16):5439-46.
Score: 0.055
-
Kelly K, Mikhaeel-Kamel N, Pan Z, Murphy J, Prindiville S, Bunn PA. A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res. 2000 Sep; 6(9):3474-9.
Score: 0.042
-
Bunn PA, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res. 1998 May; 4(5):1087-100.
Score: 0.036
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|